The use of simulation-based sensitivity analyses is fundamental for evaluating and comparing candidate designs of future clinical trials. In this context, sensitivity analyses are especially useful to
Adaptive two-stage design with treatment selection, also called seamless Phase II/III design, has been recognized to save sample size and time to enhance the development of effective treatments. These
Unblinded interim analyses in clinical trials with adaptive designs are gaining increasing popularity. Here, the type I error rate is controlled by defining an appropriate conditional error function.
